TRANSVAC is a pan-European Research Infrastructure project dedicated to accelerate vaccine development. It brings together leading European groups with longstanding experience in the field of vaccines.

TRANSVAC is uniquely positioned to set up a Bio-Holding to transform European vaccine space.

**PAST:**
**BUILDING THE CORE**
2009-2017

Core infrastructure with a limited number of partners and services for human prophylactic vaccines.

**TODAY:**
**EXPANSION**
2017-2021

Expanded infrastructure to 25+ partners and broadened services and support to veterinary and human vaccines (prophylactic and therapeutic).

**FUTURE:**
**HYBRID BIO-HOLDING**
2021+

Create a Bio-Holding dedicated to business building to solidify impact at scale.

Vaccine development is our best bet to tackle epidemic outbreaks and pandemics, but it’s time consuming and complex. Despite recent mobilization, researchers still have limited access to capabilities to transfer their discovery into clinical development and commercialization.

~70 TECHNICAL SERVICES ACROSS THE R&D PIPELINE

>60 VACCINE DEVELOPMENT PROJECTS

OPERATES IN ~10 EUROPEAN COUNTRIES

TRANSVAC is a pan-European Research Infrastructure project dedicated to accelerate vaccine development. It brings together leading European groups with longstanding experience in the field of vaccines.

How to get involved?
TRANSVAC will establish a diverse portfolio of vaccine projects where one can invest.

TRANSVAC is well equipped to support the acceleration of successful vaccine businesses

**TRACK RECORD OF VALUE CHAIN AND TRANSVERSAL SERVICES***

- Assays & Models
- Technology
- Adjuvants
- Regulatory and Clinical expertise
- Training
- Network

**TRANSVAC’S PATH FORWARD IS TO FOCUS ON BUSINESS BUILDING**

- Active investor scouting and outreach support
- Evaluating commercial viability
- Portfolio Management
- Funding
- Business Building and Coaching

**TRANSVAC will deliver commercial impact at scale as a vaccine business building entity**

**WHAT WOULD IT TAKE US TO GET THERE?**

<table>
<thead>
<tr>
<th>YEAR 1</th>
<th>YEAR 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receive investments</td>
<td>Continue building out portfolio of vaccines candidates</td>
</tr>
<tr>
<td>Expand service offer</td>
<td>1st performance evaluation milestone</td>
</tr>
<tr>
<td>Briefing pack for the first candidates</td>
<td>First subsidiaries confirmed</td>
</tr>
<tr>
<td>Activate management team with strategic &amp; commercial expertise</td>
<td>Onboard &amp; start securing deals for additional vaccine candidates</td>
</tr>
</tbody>
</table>

**CONTACT US**

European Vaccine Initiative (EVI)
transvacinfo@euvaccine.eu
0049 17660863372

**CONNECT**

www.transvac.org/transvac-ds
European Vaccine Initiative
@EuropeVaccine

**NETWORK**

25 PARTNERS

**FUNDER**

EUROPEAN UNION

**TIMELINE**

1 JUNE 2020 - 31 MAY 2022

**COORDINATOR**

EUROPEAN VACCINE INITIATIVE

---

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 951668.